Number needed to treat: difference between revisions
Diff·revision 2 → 3·22:53, 17 Oct 2024
Difference between revision 2 and revision 3 of Number needed to treat. 6 lines changed; the page grew by 628 bytes.
| Revision 2 — 11:28, 6 Oct 2024 AnalyticalAnnie (talk) add the PMID 1,122 bytes ±0 | Revision 3 — 22:53, 17 Oct 2024 TriumphThad (talk) expand §Number needed to harm 1,750 bytes +628 | ||
|---|---|---|---|
| 11 | Its value is that it expresses effect on an absolute scale. A relative risk reduction of 20% describes a large benefit where the baseline risk is high and a negligible one where it is low; the number needed to treat carries the baseline risk within it.{{r|laupacis1988}} | 11 | Its value is that it expresses effect on an absolute scale. A relative risk reduction of 20% describes a large benefit where the baseline risk is high and a negligible one where it is low; the number needed to treat carries the baseline risk within it.{{r|laupacis1988}} |
| 12 | 12 | ||
| + | 13 | == Calculation == | |
| + | 14 | {{math|\text{NNT} = 1 / (\text{risk}_{\text{control}} - \text{risk}_{\text{treated}})}} | |
| + | 15 | ||
| + | 16 | For [[SELECT trial|SELECT]], the primary composite occurred in 8.0% of the placebo group and 6.5% of the semaglutide group over a mean 39.8 months. The absolute risk reduction is 1.5 percentage points, so the number needed to treat is 1/0.015 ≈ 67 over roughly 3.3 years.{{r|lincoff2023}} | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |
| 15 | <ref name="laupacis1988">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> | 20 | <ref name="laupacis1988">Laupacis A, Sackett DL, Roberts RS. "An assessment of clinically useful measures of the consequences of treatment." ''New England Journal of Medicine'' 318(26):1728–1733 (1988). PMID 3374545.</ref> |
| + | 21 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | |
| 16 | 22 | ||
| 17 | {{DEFAULTSORT:Number needed to treat}} | 23 | {{DEFAULTSORT:Number needed to treat}} |